1. Introduction
===============

Tetraprenylated purine alkaloids and their derivatives are relatively uncommon in nature \[[@B1-marinedrugs-12-00672],[@B2-marinedrugs-12-00672]\]. They are structurally characterized by a methyl group at N-3 and a tetraprenyl chain at N-7 in the hypoxanthine core. Malonganenone A \[[@B3-marinedrugs-12-00672]\], the first typical representative of this series, was isolated from the gorgonian *Leptogorgia gilchristi*, collected in Ponto Malongane, Mozambique in 2006. Until now, only 14 analogues have been reported from marine organisms \[[@B3-marinedrugs-12-00672],[@B4-marinedrugs-12-00672],[@B5-marinedrugs-12-00672]\], some of which exhibited antitumor activity \[[@B4-marinedrugs-12-00672],[@B5-marinedrugs-12-00672]\]. Although the genus *Echinogorgia* is highly prolific in the South China Sea, only a few species of *Echinogorgia* have been chemically investigated, which led to the isolation of a series of metabolites including sterols \[[@B6-marinedrugs-12-00672],[@B7-marinedrugs-12-00672],[@B8-marinedrugs-12-00672],[@B9-marinedrugs-12-00672],[@B10-marinedrugs-12-00672],[@B11-marinedrugs-12-00672],[@B12-marinedrugs-12-00672]\], alkaloids \[[@B11-marinedrugs-12-00672],[@B12-marinedrugs-12-00672],[@B13-marinedrugs-12-00672],[@B14-marinedrugs-12-00672]\], sesquiterpenes \[[@B14-marinedrugs-12-00672],[@B15-marinedrugs-12-00672],[@B16-marinedrugs-12-00672]\], ceramides \[[@B17-marinedrugs-12-00672]\], and coumarins \[[@B18-marinedrugs-12-00672]\]. In our screening program aimed at discovering new biologically active natural products from marine organisms of the South China Sea \[[@B19-marinedrugs-12-00672]\], a fraction of the CH~2~Cl~2~/MeOH extract of *E. pseudosassapo* showed inhibitory activity towards phosphodiesterases (PDEs)-4D, 5A, and 9A. Subsequent chemical investigation resulted in the purification of six new tetraprenylated alkaloids, malonganenones L--Q (**1**--**6**, [Figure 1](#marinedrugs-12-00672-f001){ref-type="fig"}, [Supplementary Figures S1--S31](#marinedrugs-12-00672-s001){ref-type="supplementary-material"}). The resulting inhibitory activity screening against PDE4D, PDE5A, and PDE9A showed that compounds **1** and **6** exhibited moderate activities against PDE4D with IC~50~ values of 8.5 and 20.3 µM, respectively. The present report describes the isolation, structure elucidation, and PDEs inhibitory activities of these tetraprenylated alkaloids.

![Structures of malonganenones L--Q (**1**--**6**).](marinedrugs-12-00672-g001){#marinedrugs-12-00672-f001}

2. Results and Discussion
=========================

2.1. Structural Elucidation of New Compounds
--------------------------------------------

The CH~2~Cl~2~/MeOH (v/v, 1:1) extract of the gorgonian was subjected to chromatography using Sephadex LH-20 followed by silica gel and HPLC separations to yield compounds **1**--**6**.

Compound **1**, a colorless oil, exhibited a molecular formula of C~26~H~36~N~4~O~2~ as determined by HRESIMS (\[M + Na\]^+^, 459.2721, calcd. 459.2736), implying 11 double bond equivalents (DBE). The IR absorption bands at 1709 and 1610 cm^−1^ indicated the presence of two carbonyls. The ^1^H NMR spectrum of **1**([Table 1](#marinedrugs-12-00672-t001){ref-type="table"}) showed signals for two aromatic singlets \[δ~H~ 8.26 (H-2) and 7.69 (H-8)\], four olefinic protons \[δ~H~ 6.07 (H-14′), 5.45 (H-2′), 5.19 (H-10′), and 5.05 (H-6′)\], five vinylic methyls \[δ~H~ 2.10 (H-17′), 1.84 (H-16′), 1.77 (H-20′), 1.58 (H-18′), and 1.56 (H-19′)\], one heteroatom-functionalized methyl \[δ~H~ 3.86 (H-10)\], and a series of aliphatic methylene multiplets. The ^13^C NMR spectrum of **1**([Table 2](#marinedrugs-12-00672-t002){ref-type="table"}) resolved 26 resonances attributable to five double bonds (δ~C~ 155.5 C, 122.9 CH; 147.3 C, 115.0 C; 143.4 C, 117.6 CH; 135.5 C, 123.5 CH; and 129.6 C, 129.0 CH), two carbonyls (δ~C~ 199.3 and 162.0), two imines (δ~C~ 147.7 and 140.3), five vinylic methyls (δ~C~ 27.7, 20.6, 16.5, 16.4, and 16.0), a *N*-methyl (δ~C~ 35.0), and six sp^3^ methylenes (δ~C~ 55.3, 44.5, 39.4, 39.3, 26.7, and 26.1). As nine of the eleven DBE were accounted for by abovementioned unsaturated functional groups, the remaining two DBE required that **1** was bicyclic. The collective spectroscopic information pointed clearly to a fused diterpene-*N*-methylhypoxanthine structure, which bore a high similarity to that of malonganenone D \[[@B4-marinedrugs-12-00672]\]. The *N*-methylhypoxanthine moiety of **1** was readily identified by comparison of its NMR data with that of malonganenone D, which gave almost identical ^13^C NMR data regarding to this portion. The tetraprenyl side-chain of **1** was deduced from detailed analysis of COSY and HMBC data ([Figure 2](#marinedrugs-12-00672-f002){ref-type="fig"}). ^1^H--^1^H COSY correlations revealed four spin systems: (**a**) H-1′/H-2′/H-3′/H~3~-20′; (**b**) H-4′/H-5′/H-6′/H-7′/H~3~-19′; (**c**) H-8′/H-9′/H-10′/H-11′/H~3~-18′; and (**d**) H-14′/H-15′/H-16′ or H-17′. The connections from **a** to **c** were achieved by HMBC correlations of H-20′/C-4′ and H-19′/C-8′. The fragments **c** and **d** were linked via a methylene and a ketone (C-13) by HMBC correlations of H-18′/C-12′, H-12′/C-13′, and H-14′/C-13′. The geometries of the three olefins in the tetraprenyl side-chain were established from analysis of both ^13^C chemical shift and NOE data. The ^13^C chemical shifts of the vinylic methyls of C-18′, C-19′, and C-20′ (δ~C~ 16.4, 16.0, and 16.5, respectively) suggested the *E* geometries for ∆^10′^, ∆^6′^, and ∆^2′^ as the vinyl methyl corresponding to *Z* geometry are known to resonate at around 25 ppm \[[@B4-marinedrugs-12-00672]\]. This was further supported by NOE correlations ([Figure 2](#marinedrugs-12-00672-f002){ref-type="fig"}) of H-9′/H-18′ and H-10′/H-12′, H-5′/H-19′ and H-6′/H-8′, and H-1′/H-20′ and H-2′/H-4′, respectively. Finally, the tetraprenyl side-chain was attached to N-7 by HMBC correlations from H-1′ to C-5 and C-8. Thus, compound **1** was determined as depicted and given the trivial name malonganenone L.
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###### 

^1^H NMR spectroscopic data for malonganenones L--Q (**1**--**6**) (δ in ppm, *J* in Hz).

  No.   1 ^a^           2 ^a^           3 ^a^           4 ^b^           5 ^b^           6 ^b^
  ----- --------------- --------------- --------------- --------------- --------------- -------------------
  1                                                     7.23, brs                       7.22, brs
  2     8.26, br s      8.57, br s      8.62, br s      8.23, s         8.23, s         8.23, s
  8     7.69, s         7.73, s         7.73, s         7.59, s         7.59, s         7.57, s
  10    3.86, s         3.94, s         3.95, s         3.13, s         3.13, s         3.13, s
  11                                                    2.84, s         2.84, s         2.84, d (4.7)
  1′    5.07, d (7.3)   5.09, d (7.2)   5.08, d (7.4)   4.90, d (7.0)   4.90, d (7.0)   4.89, d (7.1)
  2′    5.45, t (7.0)   5.47, t (6.9)   5.47, t (6.9)   5.40, t (7.1)   5.41, t (7.0)   5.39, t (7.0)
  4′    2.08, m         2.11, m         2.11, m         2.07, m         2.08, m         2.09, m
  5′    2.09, m         2.11, m         2.12, m         2.12, m         2.13, m         2.13, m
  6′    5.05, m         5.08, m         5.07, m         5.14, t (6.2)   5.14, t (6.1)   5.14, t (6.3)
  8′    1.98, m         1.99, m         1.97, m         2.01, m         2.01, m         2.02, m
  9′    2.04, m         2.07, m         1.55, m         2.12, m         2.12, m         1.56, m
  10′   5.19, t (6.4)   5.32, t (6.6)   2.06, m         5.26, t (6.8)   5.30, t (6.3)   2.55, br t, (7.9)
  12′   2.99, s         3.09, s         6.00, br s      3.01, s         3.12, s         6.08, br s
  14′   6.07, br s      6.06, br s      6.04, br s      6.17, br s      6.15, br s      6.10, br s
  16′   1.84, s         1.87, s         1.87, d (0.9)   1.86, d (1.1)   1.87, d (1.1)   1.86, d (1.0)
  17′   2.10, s         2.13, s         2.13, d (1.0)   2.09, d (1.1)   2.09, d (1.0)   2.12, d (1.0)
  18′   1.58, s         1.69, s         2.15, d (1.2)   1.61, s         1.66, d (1.2)   1.87, d (1.3)
  19′   1.56, s         1.58, s         1.58, s         1.59, s         1.60, s         1.62, s
  20′   1.77, s         1.79, s         1.80, s         1.79, s         1.79, s         1.79, s

^a^ Measured at 400 MHz in CDCl~3~; ^b^ Measured at 400 MHz in Acetone-*d*~6~.
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###### 

^13^C NMR spectroscopic data for malonganenones L--Q (**1**--**6**) (δ in ppm).

  No.   1 ^a^   2 ^a^   3 ^a^   4 ^b^   5 ^b^   6 ^b^
  ----- ------- ------- ------- ------- ------- -------
  2     147.7   148.1   148.1   163.3   163.3   163.3
  4     147.3   147.2   147.2   141.8   141.8   141.8
  5     115.0   115.2   115.2   118.2   118.2   118.2
  6     162.0   160.4   160.3   160.9   160.9   161.0
  8     140.3   140.7   140.8   137.6   137.6   137.6
  10    35.0    35.5    35.5    31.9    31.9    31.9
  11                            26.1    26.1    26.3
  1′    44.5    44.6    44.7    45.2    45.2    45.2
  2′    117.6   117.3   117.4   120.5   120.5   120.4
  3′    143.4   143.7   143.7   142.0   142.0   142.0
  4′    39.4    39.5    39.4    40.1    40.2    40.2
  5′    26.1    26.1    26.1    27.0    26.9    26.9
  6′    123.5   123.6   123.9   124.8   124.8   124.8
  7′    135.5   135.5   135.4   135.8   135.8   136.0
  8′    39.3    39.5    39.1    40.1    40.3    40.6
  9′    26.7    26.9    25.8    27.4    27.7    27.2
  10′   129.0   128.2   40.8    129.4   128.7   33.8
  11′   129.6   129.2   157.8   130.7   130.2   158.6
  12′   55.3    47.9    125.7   55.8    48.3    126.9
  13′   199.3   198.6   191.7   198.8   198.1   191.0
  14′   122.9   123.0   126.3   123.7   124.0   127.0
  15′   155.5   155.8   154.2   155.0   155.3   154.2
  16′   27.7    27.7    27.7    27.5    27.5    27.6
  17′   20.6    20.7    20.5    20.5    20.5    20.4
  18′   16.4    24.1    19.1    16.5    24.4    25.5
  19′   16.0    16.0    15.9    16.1    16.1    16.0
  20′   16.5    16.6    16.6    16.5    16.5    16.5

^a^ Measured at 100 MHz in CDCl~3~; ^b^ Measured at 100 MHz in Acetone-*d*~6~.

![Key ^1^H--^1^H COSY (--), HMBC (→) and NOESY (dashed arrows) correlations for **1** and **4**.](marinedrugs-12-00672-g002){#marinedrugs-12-00672-f002}

Compound **2** exhibited the same molecular formula of C~26~H~36~N~4~O~2~ as **1** on the basis of the HRESIMS data (\[M + Na\]^+^, 459.2725, calcd. 459.2736). The NMR spectroscopic data of **2** ([Table 1](#marinedrugs-12-00672-t001){ref-type="table"} and [Table 2](#marinedrugs-12-00672-t002){ref-type="table"}) was very similar to that of **1**. In comparison with **1**, the ^13^C NMR spectroscopic data for **2** differed significantly about ∆^10′^ moiety, with the upfield-shifted carbon at C-12′ and the downfield-shifted vinyl methyl at C-18′ (δ~C~ 55.3 and 16.3 in **1**; δ~C~ 47.9 and 24.1 in **2**, respectively). This indicated that ∆^10′^ in **2** adopts a *Z* configuration. Similar ^13^C NMR changes were also reported in malonganenone I \[[@B5-marinedrugs-12-00672]\], which possessed the same *Z* configuration of ∆^10′^ as **2**. Thus, compound **2** was determined as depicted and named malonganenone M.

Compound **3** had a molecular formula of C~26~H~36~N~4~O~2~ as established by HRESIMS data. The ^1^H and ^13^C NMR data of **3**([Table 1](#marinedrugs-12-00672-t001){ref-type="table"} and [Table 2](#marinedrugs-12-00672-t002){ref-type="table"}) showed high similarity to those of **1** except that the ∆^10′^ double bond in **1** was migrated to ∆^11′^, forming a conjugated system with the C-13′ carbonyl. This was suggested by the significant downfield-shifted carbon at C-11′ and the upfield-shifted carbon at C-13′ as compared with those of **1** (δ~C~ 129.6 and 199.3 in **1**; δ~C~ 157.8 and 191.7 in **3**, respectively), and by the presence of a singlet olefinic signal (δ~H~ 6.00, H-12′) in the ^1^H NMR spectra of **3** instead of a triplet olefinic signal (δ~H~ 5.19, t, *J* = 6.4 Hz, H-10′) in **1**. The configuration of ∆^11′^ in **3** was established to be *E* by the characteristic chemical shift of the vinylic methyl at C-18′ (δ~C~ 19.1) and by comparison of its NMR data with those of reported. Therefore, the structure of compound **3** was determined as depicted and given the trivial name malonganenone N.

Compound **4** exhibited an \[M − H\]^−^ ion at *m*/*z* 467.3021 (calcd. for C~27~H~39~N~4~O~3~, 467.3022), suggesting the molecular formula C~27~H~40~N~4~O~3~ (ten DBE). The ^1^H and ^13^C NMR spectra of **4** ([Table 1](#marinedrugs-12-00672-t001){ref-type="table"} and [Table 2](#marinedrugs-12-00672-t002){ref-type="table"}) bore a resemblance to those of **1**, with the notable differences occurring in the hypoxanthine core. The NMR spectra of **4** showed the presence of an *N*-methylamide (δ~H~ 2.84, H-11; δ~C~ 26.1, C-11) and an *N*-methylformamide (δ~H~ 8.23, H-2 and 3.13, H-10; δ~C~ 163.3, C-2 and 31.9, C-10) groups, which were identical to those previously reported in malonganenones B, F, and G, indicating that **4** possessed the same trisubstituted imidazole ring. This was further supported by HMBC correlations ([Figure 2](#marinedrugs-12-00672-f002){ref-type="fig"}) of H~3~-11/C-6, H~3~-10/C-4, and H-2/C-10. Thus, the structure of compound **4** was determined as depicted and given the trivial name malonganenone O.

Compound **5** had a molecular formula C~27~H~40~N~4~O~3~ by analysis of the HRESIMS data. Comparing the NMR data ([Table 1](#marinedrugs-12-00672-t001){ref-type="table"} and [Table 2](#marinedrugs-12-00672-t002){ref-type="table"}) of **5** and **4**, it appeared that the former had a *Z* configuration of ∆^10′^ instead of an *E* configuration of ∆^10′^ in **4**. This was suggested by the upfield-shifted carbon at C-12′ and the downfield-shifted vinyl methyl at C-18′ (δ~C~ 48.3 and 24.4 in **5**; δ~C~ 55.8 and 16.5 in **4**, respectively). Thus, the structure of compound **5** was determined as depicted and given the trivial name malonganenone P.

The molecular formula of compound **6** was established as C~27~H~40~N~4~O~3~ by HRESIMS. The NMR data of **6** ([Table 1](#marinedrugs-12-00672-t001){ref-type="table"} and [Table 2](#marinedrugs-12-00672-t002){ref-type="table"}) showed high similarity to that of **4** except that the ∆^10′^ double bond in **6**was migrated to ∆^11′^, forming a conjugated system with the C-13′ carbonyl. This was further suggested by the significant downfield-shifted carbon at C-11′ and the upfield-shifted carbon at C-13′ as compared with those of **4** (δ~C~ 130.7 and 198.8 in **4**; δ~C~ 158.6 and 191.0 in **6**, respectively), and by the presence of a singlet olefinic signal (δ~H~ 6.08, H-12′) in the ^1^H NMR spectra of **6** instead of a triplet olefinic signal (δ~H~ 5.26, t, *J* = 6.8 Hz, H-10′) in **4**. The characteristic chemical shift of the vinylic methyl at C-18′ (δ~C~ 25.5) indicated the *Z* configuration of ∆^11′^ in **6**. Thus, the structure of **6** was determined as depicted and given the trivial name malonganenone Q.

2.2. *In Vitro* Inhibitory Activity Screening against PDEs
----------------------------------------------------------

Compounds **1**--**6** were screened for their inhibitory activities against PDE4D, PDE5A, and PDE9A by using our previously reported methods \[[@B20-marinedrugs-12-00672],[@B21-marinedrugs-12-00672],[@B22-marinedrugs-12-00672],[@B23-marinedrugs-12-00672]\]. As shown in [Table 3](#marinedrugs-12-00672-t003){ref-type="table"}, all compounds exhibited inhibition at 50 µM against PDE4D with degree of inhibition from 72% to 85%, while displaying weaker activities against PDE5A and PDE9A. The two most active compounds, **1** and **6**, were selected to test for the half maximal inhibitory concentration (IC~50~), which gave IC~50~ values of 8.5 and 20.3 µM, respectively ([Figure 3](#marinedrugs-12-00672-f003){ref-type="fig"}).
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###### 

Inhibitory activities of compounds **1**--**6** at 5 µM and 50 µM towards PDE4D, PDE5A and PDE9A.

  Compound   Inhibition (%) of Compounds at 50 µM        Inhibition (%) of Compounds at 5 µM                    
  ---------- -------------------------------------- ---- ------------------------------------- -- ------ ------ ------
  **1**      85                                     53   18                                       17     11     \<10
  **2**      72                                     32   15                                       \<10   \<10   \<10
  **3**      81                                     35   27                                       17     \<10   10
  **4**      79                                     38   \<10                                     18     \<10   \<10
  **5**      75                                     36   11                                       14     \<10   \<10
  **6**      85                                     38   15                                       18     \<10   \<10

![Inhibition of phosphodiesterase-4D by compounds **1** and **6** (rolipram as positive control).](marinedrugs-12-00672-g003){#marinedrugs-12-00672-f003}

3. Experimental Section
=======================

3.1. General Experimental Procedures
------------------------------------

UV spectra were recorded on a Shimadzu UV-2450 spectrophotometer. IR spectra were determined on a Bruker Tensor 37 infrared spectrophotometer with KBr disks. NMR spectra were measured on a Bruker AM-400 spectrometer at 25 °C. ESIMS and HRESIMS were carried out on a Finnigan LC Q^DECA^ instrument. A Shimadzu LC-20 AT equipped with an SPD-M20A PDA detector was used for HPLC, a YMC-pack ODS-A column (250 × 10 mm, 5 µm, 12 nm) and a chiral column (Phenomenex Lux, cellulose-2, 250 × 10 mm, 5 µm) was used for semipreparative HPLC separation. Silica gel (300--400 mesh, Qingdao Marine Chemical Co., Ltd., Qingdao, Shandong, China), C~18~ reversed-phase (Rp-C~18~) silica gel (12 nm, 50 µm, YMC Co., Ltd., Kyoto, Japan), Sephadex LH-20 gel (Amersham Biosciences, Piscataway, NJ, USA), used for column chromatography (CC). All solvents used were of analytical grade (Guangzhou Chemical Reagents Company, Ltd., Guangzhou, Guangdong, China).

3.2. Animal Material
--------------------

The gorgonian *E. pseudosassapo* was collected at a depth of 18--25 m in 29 July 2012 in Daya Bay of Guangdong Province, China and frozen immediately after collection, and were identified by one of the authors (Cheng-Qi Fan). A voucher specimen (accession number: LSH201207) has been deposited at the School of Pharmaceutical Sciences, Sun Yat-sen University, China.

3.3. Extraction and Isolation
-----------------------------

Specimens of *E. pseudosassapo* (550 g, wet weight) were extracted with CH~2~Cl~2~/MeOH (1:1, 3 × 1 L) at room temperature (rt) to give 13.7 g of crude extract. The crude extract was subjected to silica gel column chromatography eluted with a CH~2~Cl~2~/MeOH gradient (9:1→1:9) to afford five fractions (Fr. I--V). Fr. III (1.4 g) was chromatographed over Sephadex LH-20 (CH~2~Cl~2~/MeOH, v/v, 1:1), followed by Rp-C~18~ silica gel eluted with a CH~3~CN/H~2~O gradient (5:5→10:0) to obtain four sub-fractions (Fr. IIIa--IIId). Fr. IIIb was further separated by HPLC equipped with a chiral column (CH~3~CN, 3 mL/min) to afford **1** (17 mg, *t*~R~ 17 min) and **2** (4.9 mg, *t*~R~ 20 min). Fr. IIId was purified by repeating the HPLC conditions described above to yield **4** (11 mg, *t*~R~ 23 min) and **5** (3.7 mg, *t*~R~ 27 min). Fr. IIIc was chromatographed by HPLC equipped with an ODS-A column (CH~3~CN/H~2~O, 90:10, 3 mL/min) to afford **3** (5.2 mg, *t*~R~ 15 min) and **6** (5.1 mg, *t*~R~ 20min).

**Malonganenone L**(**1**): colorless oil; UV (MeOH) λ~max~ (log ε) 211 (4.42), 225 (4.38), 253 (4.31) nm; IR ν~max~ 3145, 1709, 1610, 1464, 1250, 1128, 1060 cm^−1^; ^1^H and ^13^C NMR, see [Table 1](#marinedrugs-12-00672-t001){ref-type="table"} and [Table 2](#marinedrugs-12-00672-t002){ref-type="table"}; HRESIMS \[M + Na\]^+^ *m*/*z* 459.2721 (calcd. for C~26~H~36~N~4~O~2~Na, 459.2736).

**Malonganenone M**(**2**): colorless oil; UV (MeOH) λ~max~ (log ε) 209 (4.22), 225 (4.17), 254 (4.06) nm; IR ν~max~ 3011, 1714, 1607, 1458, 1240, 1123, 1046 cm^−1^; ^1^H and ^13^C NMR, see [Table 1](#marinedrugs-12-00672-t001){ref-type="table"} and [Table 2](#marinedrugs-12-00672-t002){ref-type="table"}; HRESIMS \[M + Na\]^+^ *m*/*z* 459.2725 (calcd. for C~26~H~36~N~4~O~2~Na, 459.2736).

**Malonganenone N**(**3**): colorless oil; UV (MeOH) λ~max~ (log ε) 208 (3.68), 223 (3.60), 254 (3.16) nm; IR ν~max~ 2937, 1732, 1627, 1439, 1379, 1215, 1136, 1039 cm^−1^; ^1^H and ^13^C NMR, see [Table 1](#marinedrugs-12-00672-t001){ref-type="table"} and [Table 2](#marinedrugs-12-00672-t002){ref-type="table"}; HRESIMS \[M + Na\]^+^ *m*/*z* 459.2725 (calcd. for C~26~H~36~N~4~O~2~Na, 459.2736).

**Malonganenone O**(**4**): colorless oil; UV (MeOH) λ~max~ (log ε) 211 (4.39), 249 (4.22) nm; IR ν~max~ 2932, 1744, 1654, 1514, 1445, 1218, 1127, 1033 cm^−1^; ^1^H and ^13^C NMR, see [Table 1](#marinedrugs-12-00672-t001){ref-type="table"} and [Table 2](#marinedrugs-12-00672-t002){ref-type="table"}; HRESIMS \[M − H\]^−^ *m*/*z* 467.3021 (calcd. for C~27~H~39~N~4~O~3~, 467.3022).

**Malonganenone P**(**5**): colorless oil; UV (MeOH) λ~max~ (log ε) 210 (4.27), 254 (4.02) nm; IR ν~max~ 2933, 1674, 1621, 1437, 1220, 1128, 1018 cm^−1^; ^1^H and ^13^C NMR, see [Table 1](#marinedrugs-12-00672-t001){ref-type="table"} and [Table 2](#marinedrugs-12-00672-t002){ref-type="table"}; HRESIMS \[M + Na\]^+^ *m*/*z* 491.2994 (calcd. for C~27~H~40~N~4~O~3~Na, 491.2998).

**Malonganenone Q**(**6**): colorless oil; UV (MeOH) λ~max~ (log ε) 212 (4.52), 257 (4.46) nm; IR ν~max~ 2932, 1664, 1623, 1532, 1443, 1224, 1057 cm^−1^; ^1^H and ^13^C NMR, see [Table 1](#marinedrugs-12-00672-t001){ref-type="table"} and [Table 2](#marinedrugs-12-00672-t002){ref-type="table"}; HRESIMS \[M + Na\]^+^ *m*/*z* 491.2994 (calcd. for C~27~H~40~N~4~O~3~Na, 491.2998).

4. Conclusions
==============

In our continuing investigation on the chemical constituents of marine invertebrates collected from the South China Sea, six new tetraprenylated alkaloids, designated as malonganenones L--Q (**1**--**6**), were isolated from the gorgonian *Echinogorgia pseudossapo*. The structures of **1**--**6** featuring a methyl group at N-3 and a tetraprenyl chain at N-7 in the hypoxanthine core were established by extensive spectroscopic analyses. Compounds **1**--**6** were tested for their inhibitory activity against the phosphodiesterases (PDEs)-4D, 5A, and 9A, and compounds **1** and **6** exhibited moderate inhibitory activity against PDE4D with IC~50~ values of 8.5 and 20.3 µM, respectively. Phosphodiesterase-4 (PDE4), which specifically catalyzes the hydrolysis of cyclic adenosine monophosphate (cAMP), is a therapeutic target of high interest for central nervous system (CNS), inflammatory, and respiratory diseases \[[@B24-marinedrugs-12-00672]\]. Natural PDE4 inhibitors are very rare. To the best of our knowledge, this is the first investigation of this group of compounds on the inhibitory activity of the phosphodiesterases.
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